aTyr Pharma (LIFE) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital
March 15, 2024 6:39 AM EDTRBC Capital analyst Kennan MacKay lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $16.00 (from $19.00) while maintaining a Outperform rating.
The analyst comments "From LIFEs YE call, Early Access Program demand underscores the enthusiasm across sites as the ph.III EFZO-FIT... More



